US Patent

US10058615 — Semifluorinated alkane compositions

Method of Use · Assigned to Novaliq GmbH · Expires 2033-09-12 · 7y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel compositions of semifluorinated alkanes used as medicines for topical administration to an eye or ophthalmic tissue.

USPTO Abstract

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1900 Miebo

Patent Metadata

Patent number
US10058615
Jurisdiction
US
Classification
Method of Use
Expires
2033-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.